WHO Prequalified New Typhoid Vaccine in August
The addition of EuTYPH-C to the WHO-approved list helps international agencies expand vaccine access.
Updated on Sept. 27, 2026 in Diseases — General
Live Poll
Should international health agencies prioritize lower-cost vaccine suppliers to improve global health equity?
In August 2026, the World Health Organization granted prequalification to the EuTYPH-C typhoid conjugate vaccine. This approval allows the vaccine to enter international procurement bidding to help address the 6.2 million cases of typhoid reported worldwide in 2023.
Why it matters
Diversifying the supply of typhoid conjugate vaccines is a priority for procurement agencies aiming to lower costs and ensure reliable access for children. The vaccine provides immunity to infants as young as 6 months, a critical demographic for preventing the 72,000 deaths caused by the disease in 2023.
The vaccine underwent Phase 3 clinical trials in Kenya and Senegal to support the prequalification process. These trials were supported by a 4 billion won investment, with EuBiologics contributing a 50 percent share of the total study funding.
The players
World Health Organization
The United Nations agency responsible for international public health, setting global standards for vaccine efficacy and safety.
EuBiologics
A biotechnology company that develops vaccines and therapeutics, currently focused on expanding access to typhoid prevention.
RIGHT Foundation
A global health funding organization that supports research and development for infectious disease prevention.
UNICEF
The agency responsible for providing humanitarian and developmental aid to children, serving as a primary purchaser of global vaccines.
The details
The EuTYPH-C vaccine uses conjugate technology to train the immune system to recognize Salmonella Typhi bacteria, enabling protection for children as young as 6 months. By securing WHO prequalification, the manufacturer can now compete for large-scale international contracts. Agencies like UNICEF look to these expanded supply chains to stabilize global distribution networks and reduce regional reliance on a limited number of existing suppliers.
Timeline
2018: The RIGHT Foundation was established.
2021: The RIGHT Foundation selected EuBiologics for vaccine funding.
2023: Worldwide typhoid cases and deaths were estimated at 6.2 million and 72,000 respectively.
August 2026: The WHO officially granted prequalification to EuTYPH-C.
H2 2027: Targeted timeline for the initial UNICEF vaccine allocation.
Health Landscape
The global typhoid prevention strategy currently relies on a limited pool of prequalified suppliers, mostly based in India. Expanding this list through the WHO vaccine prequalification program increases the resilience of international procurement networks.
Increased vaccine supply typically stabilizes access to routine immunizations in areas with high disease burdens. If you live in an region affected by typhoid, consult your local physician regarding the current availability of conjugate vaccines for your children.
The takeaway
Prequalification expands the global supply of vaccines, making it easier for health organizations to reach vulnerable populations. Discuss the current vaccination schedule for typhoid with your healthcare provider to ensure your family remains protected according to regional guidelines.
What happens next
EuBiologics expects to receive a Korean export license for its single-dose vial version in October 2026, followed by a formal request for WHO variation recognition in November 2026.
Further reading
Learn more about global health initiatives at Diseases — General.
Source note: This article includes information reported by The Korea Herald.
Live Poll
Should international health agencies prioritize lower-cost vaccine suppliers to improve global health equity?
